◆英語タイトル:FLX Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11077
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate the cancer. The company has advanced into the clinic a dual-inhibitor drug that target FLT3 and CDK4 and 6 for the treatment of cancer. FLX Bio is headquartered in South San Francisco, California, the US.
FLX Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
Partnerships 14
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
Licensing Agreements 16
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc – Key Competitors 17
FLX Bio Inc – Key Employees 18
FLX Bio Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Feb 05, 2018: FLX Bio Names Michael Giordano As Board Director 20
Jan 03, 2018: FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology 21
May 31, 2017: FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board 22
Clinical Trials 23
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate 23
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
FLX Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc, Key Competitors 17
FLX Bio Inc, Key Employees 18
List of Figures
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8